Secondary Logo

Journal Logo

Treatment of Periodontal Disease During Pregnancy: A Randomized Controlled Trial

Newnham, John P. FRANZCOG; Newnham, Ian A. FRACDS(Perio); Ball, Colleen M. RN; Wright, Michelle AssocDDentHyg; Pennell, Craig E. FRANZCOG; Swain, Jonathan MDSc(Perio); Doherty, Dorota A. PhD

doi: 10.1097/AOG.0b013e3181c15b40
Original Research

OBJECTIVE: To investigate whether treating periodontal disease prevents preterm birth and other major complications of pregnancy.

METHODS: This single-center trial was conducted across six obstetric sites in metropolitan Perth, Western Australia. Pregnant women identified by history to be at risk (n=3,737) were examined for periodontal disease. Approximately 1,000 women with periodontal disease were allocated at random to receive periodontal treatment commencing around 20 weeks of gestation (n=542) or 6 weeks after the pregnancy was completed (controls; n=540). The treatment included mechanical removal of oral biofilms together with oral hygiene instruction and motivation at a minimum of three weekly visits, with further visits if required.

RESULTS: There were no differences between the control and treatment groups in preterm birth (9.3% compared with 9.7%, odds ratio [OR] 1.05, 95% confidence interval [CI 0.7–1.58], P=.81), birth weight (3,450 compared with 3,410 g, P=.12), preeclampsia (4.1% compared with 3.4%, OR 0.82, 95% CI 0.44–1.56, P=.55), or other obstetric endpoints. There were four unexplained stillbirths in the control group and no pregnancy losses in the treated group (P=.12). Measures of fetal and neonatal well-being were similar in the two groups, including abnormalities in fetal heart rate recordings (P=.26), umbilical artery flow studies (P=.96), and umbilical artery blood gas values (P=.37). The periodontal treatment was highly successful in improving health of the gums (P<.01).

CONCLUSION: The evidence provided by the present study does not support the hypothesis that treatment of periodontal disease during pregnancy in this population prevents preterm birth, fetal growth restriction, or preeclampsia. Periodontal treatment was not hazardous to the women or their pregnancies.



Treatment of periodontal disease in midpregnancy improves oral health but does not prevent preterm birth, preeclampsia, or fetal growth restriction.

From the Schools of Women’s and Infants’ Health and Dentistry of The University of Western Australia; the Women and Infants Research Foundation of Western Australia; and the Oral Health Centre of Western Australia, Perth, Western Australia.

Supported by a 3-year project grant from the National Health and Medical Research Council of Australia (no. 353577), the Women and Infants Research Foundation of Western Australia, and Channel 7 Telethon of Western Australia. Funds were provided by Colgate-Palmolive to supplement the salaries of the dental hygienists. Oral B provided oral health care products that were given to the women at the time of treatment.

The authors thank Dr. Peter Jarman, Head of Dental Services of Western Australia, for facilitating access to peripheral dental clinics; the study hygienists, Esther Jansen, Belinda Orrock, Dagmar Toman, Lynne Patrick, and Rhona Brooksbank, and Lorraine Howard, a dental assistant, for screening and providing periodontal treatment during the study; the study midwives, Renate McLaurin, Cherry Young, Dolores Gasbarro, Desiree Cavil, Melanie Mosey, and Sally Bakker, for recruitment and data collection; and Professor John McGeachie, who assisted with the study design. The authors also thank members of the data safety monitoring committee for monitoring the safety of women participating in the study: Prof. Jan Dickinson (Chair), The University of Western Australia, and Prof. Caroline Crowther, University of Adelaide, for monitoring of the obstetric outcomes; Prof. Paul Abbott, Oral Health Centre of Western Australia and The University of Western Australia, for monitoring of the periodontal treatment; and Ms. Liz Nathan, Biostatistician, Women and Infants Research Foundation, for providing independent biostatistical advice.

Presented as an oral presentation at the 56th Annual Meeting of the Society for Gynecologic Investigation, March 17–21, 2009, Glasgow, United Kingdom.

Corresponding author: John P. Newnham, FRANZCOG, School of Women’s and Infants’ Health, The University of Western Australia, King Edward Memorial Hospital, 374 Bagot Road, Subiaco, Perth, Western Australia 6008; e-mail:

Financial Disclosure The authors did not report any potential conflicts of interest.

Despite several decades of major improvements in diagnostic and therapeutic systems used in antenatal care, the rates of many major complications of pregnancy are not decreasing, including preterm birth.1 A vital clue as to the origin of many cases of preterm birth has come from the discovery that inflammatory pathways may be involved in a high proportion of early deliveries, suggesting the presence of infection.2 Trials using antibiotics have in general failed to prevent preterm birth,3 suggesting that if the inflammation is of bacterial origin, the source may be a distant site, and one that will not respond to conventional antibiotic therapy. Periodontal disease is one possibility.4

Many case series and cohort studies have shown significant associations between periodontal disease and preterm birth,5 fetal growth restriction,4 and preeclampsia.6 Experiments using animals have also shown strong associations between periodontal pathogens and fetal death7–9 and growth restriction.7 The mechanisms by which an inflamed and infected periodontium could adversely affect the pregnant uterus and developing fetus are uncertain, although evidence suggests roles for translocation of periodontopathic organisms, and stimulation and release of inflammatory mediators and prostaglandins into the maternal circulation.10

Evidence from seven trials of treatment during pregnancy are now available, but many of the findings are in conflict and inconclusive.11 The largest of these trials, the Obstetric and Periodontal Therapy (OPT) Study, observed no beneficial effect of periodontal treatment on preterm birth or birth weight, but did observe a possible effect of preventing stillbirth, the certainty of which was unclear.12

The purpose of the present study was to perform a randomized controlled trial of treatment of periodontal disease in midpregnancy to investigate whether such treatment may prevent preterm birth, fetal growth restriction, and preeclampsia. Our study was conducted by a single group of investigators operating from a major center, with screening and treatments at six additional sites within metropolitan Perth, Western Australia.

Back to Top | Article Outline


The Smile Study was a single-center randomized controlled trial of treatment for periodontal disease in midpregnancy conducted at seven sites in one city. The protocol was approved by the ethics committees responsible for each of the study sites. Pregnant women were invited to participate in public and private antenatal clinics and offices across metropolitan Perth, Western Australia. Advertisements in the lay media and promotional material in clinical environments invited women who had concerns about the health of their gums, pain on biting, bleeding from the gums, or a history of preterm birth. We had observed in a previous study that these four items were predictive of periodontal disease (unpublished observations, 2003). Women were eligible for recruitment if they were more than 16 years of age; did not have maternal cardiac disease that would warrant the need for antibiotics for periodontal examination or treatment; had not already received periodontal treatment during the current pregnancy; had no fewer than 20 natural teeth; had a single pregnancy of more than 12 and less than 20 weeks of gestational age; did not have any known fetal anomalies or other risk factors, such as hydramnios, that would place the pregnancy at imminent risk of complications; and were able to attend regularly for periodontal treatment if required.

Periodontal screening studies were conducted at King Edward Memorial Hospital, the Oral Health Centre of Western Australia, Osborne Park Hospital, Swan Districts Hospital, Armadale Hospital, Rockingham Hospital, and Joondalup Hospital. The latter five hospitals are secondary level centers across metropolitan Perth, whereas King Edward Memorial Hospital is the tertiary-level perinatal center for the state of Western Australia. Informed written consent to conduct the screening study was obtained by a research midwife. These screening studies were performed by one of five research hygienists under the supervision of two specialist periodontists (I.N. and J.S.). The examinations were a modified Community Periodontal Index of Treatment Needs study conducted in a well-equipped dental environment.13 Each study took approximately 20 minutes to conduct. Periodontal disease was defined as presence of periodontal pockets of 4 mm or greater in depth at 12 or more probing sites in fully erupted teeth (typically excluding wisdom teeth). This definition was based on the results of a pilot study that showed that 15.4% of our general antenatal population had periodontal disease of this degree (unpublished observations, 2003). Periodontal pocketing was used to define the presence of periodontal disease rather than loss of clinical attachment because it better represents the microbial challenge and is the most frequently used criterion of current disease.

Pregnant women were invited to participate in the treatment study if the findings from the screening examination met the criteria for periodontal disease. Informed written consent for treatment was obtained by a research midwife or hygienist. A questionnaire was then administered to obtain data on demographic, dental, and medical aspects of the woman’s health.

Randomization was conducted by a research midwife or hygienist using computer randomization software specifically designed to allocate each case at random with stratification for nulliparity, history of preterm birth, and current smoking. Women found to have a periodontal disease were randomly allocated to receive periodontal treatment in midpregnancy (treatment group; n=542) or after the pregnancy was concluded (control group; n=540).

The women who were found to not have periodontal disease were provided with a written record of their examination but were not involved in the study thereafter.

Treatment was preceded by full periodontal examination, including precise measurement of periodontal pocket depth to 0.2 mm with a Florida probe (Florida Probe Corporation, FL). Data obtained by this system are recorded directly into a computer database.14 Examination also included measurement of clinical attachment loss, bleeding after probing across the full mouth, and calculation of a modified O’Leary Plaque Index.15 A treatment plan was then devised, often in consultation with a specialist periodontist, and discussed with the woman.

The primary objective of the treatment was to remove or control various biofilms that act as reservoirs for the bacterial load. Treatments were conducted either by the hygienists or periodontists and included nonsurgical débridement of the subgingival and supragingival plaque, removal of local predisposing factors such as calculus, root planing, and adjustment of overhanging restorations. Comprehensive oral hygiene instructions and motivation were provided at each visit. The advice included recommendations for tooth brushing and flossing after every meal and rinsing with 0.12% non–alcohol-based chlorhexidine mouthwash. Local anesthesia was used as required (1% lignocaine with 1:80,000 adrenalin up to a maximum dose of 4.4 mL per treatment visit). These treatment sessions were provided on three occasions at weekly intervals commencing around 20 weeks of gestation. Each woman was given $10 to reimburse for travel expenses at each treatment visit.

Four weeks after the final treatment, typically at 28 weeks of gestation, a further examination was conducted to provide a quantified assessment of the success of treatment. This assessment included a clinical examination and measurements with a Florida probe. Those women in whom the treatment had not been successful were offered a further 3-week treatment regimen (107 [19.6%] women were found to require additional treatment visits).

All women in the antenatal treatment arm of the study were examined again at 32 and 36 weeks of gestation. The success of treatment was again quantified, and oral hygiene advice and motivation were provided. Systemic antibiotics were not provided for periodontal disease.

Women allocated to the postnatal (control) group were offered periodontal care after the birth, commencing 6 weeks after delivery. They had no further contact with any members of the research team until their pregnancy was concluded. The postnatal care involved the same 3-week treatment protocol as for women in the antenatal treatment group. A follow-up visit was then offered 4 weeks later to assess the effectiveness of the treatment.

All medical, nursing, and perinatal pathology staff members were unaware of the treatment allocation of each woman in the study, and health care was provided according to standard protocols within each clinic and hospital. Details of all medical, obstetric, and neonatal outcomes were extracted from the medical records by research midwives who were also blinded to the treatment allocation. Twenty-four women had moved interstate or overseas, and their obstetric and neonatal outcomes were obtained by telephone (nine in the control and 15 in the antenatal treatment group, respectively). Stillbirth in Australia is defined as death of the unborn fetus after 20 completed weeks of gestation or more than 400 g birth weight.

The primary hypothesis was that treatment of periodontal disease during pregnancy reduces the rate of preterm birth from 12% to 7%. A sample size of 1,082 women was required to detect this reduction in the preterm birth rate with 80% (β=.20) power while using a two-sided test of proportions at 5% significance level (α=.05).

We initially planned a study with a sample size of 1,094 women, which included an interim analysis to be conducted when 60% of the study pregnancies were completed. In August 2007, the independent data safety monitoring committee recommended proceeding without an interim analysis after data on treatment safety and pregnancy outcomes from the trial conducted by Michalowicz et al12 were published.

Continuous outcomes were summarized using means and standard deviations or medians and interquartile ranges, as appropriate. Categorical outcomes were summarized using frequency distributions. Univariable comparisons of pregnancy outcomes were based on the Mann-Whitney or t test for continuous data and the χ2 or Fisher exact test for categorical data. Comparison of the rate of preterm birth adjusted for parity, smoking, and history of preterm birth was performed using logistic regression analysis with odds ratios (ORs) and their 95% confidence intervals (CIs) used to summarize the treatment effect. Supplementary univariate comparisons of gestational ages at delivery between groups were based on Kaplan-Meier survival curves and the log rank test, and a proportional hazards Cox regression model was used for adjusted analyses with hazard ratios and their CIs. Primary data analysis was performed on the intention-to-treat principle. Secondary subgroup analyses of dose response effects to treatment compared pregnancy outcomes according to the disease severity and treatment compliance during pregnancy (noncompliant women in the treatment group were excluded from this analysis). Results of this analysis were similar to those obtained when using the intention-to-treat approach and are not shown. SPSS (SPSS Inc., Chicago IL) statistical software was used for data analysis. P<.05 was considered statistically significant.

Back to Top | Article Outline


A total 6,340 women were invited to participate in the study between February 2005 and December 2007, with the final pregnancy concluding in June 2008 (Fig. 1). The women were approached either directly by research midwives within a clinical environment, or they responded by telephone to promotional material in the lay press. Of these, 3,737 women were recruited and received a screening examination of their periodontal status. These examinations identified 1,087 women (29.1%) with periodontal disease, each of whom then provided consent to participate in the treatment arm of the study. Five hundred forty-one women were allocated at random to receive periodontal treatment commencing 6 weeks after the pregnancy was concluded (control group), and 546 women were allocated at random to receive treatment commencing at 21 weeks of gestation (treatment group). Five women assigned to antenatal treatment withdrew their consent before treatment commenced. One woman was excluded when found at 19 weeks of gestation to have a multiple pregnancy. Two women had spontaneous abortions after recruitment and before their first screening examination. Follow-up data were available for all women except one in the antenatal group, who was known to have left Australia to give birth in her country of origin.



The two groups were similar in baseline maternal characteristics (Table 1): 71.6% of the women were Caucasian, 98.0% had received more than 9 years of education, the mean prepregnancy body mass index was 24.9 kg/m2, and 45.1% had experienced a previous spontaneous or induced pregnancy loss. There were no differences between the two groups in rates of preeclampsia (P=.551, OR 0.82, 95% CI 0.44–1.56) or gestational hypertension (P=.607, OR 0.88, 95% CI 0.59–1.31).

Table 1

Table 1

Four fetuses in the control group were stillborn (Tables 2 and 3). All four were from pregnancies that were uncomplicated, and their mothers were all married, had more than 12 years of education, and were nonsmokers. In each case, the perinatal pathologist classified the cause of stillbirth as unknown, and there were no features of inflammation in the fetus or placenta. All four mothers had given histories of daily occurrences of bleeding from their gums during tooth brushing, and on periodontal examination each had bleeding, inflammation, and plaque levels classified as moderate. There was a single neonatal death, occurring at 1 hour of age after preterm birth at 22 weeks of gestation. The pregnancy had been complicated by antepartum hemorrhage and was in the control group. Except for a single case of loss to follow-up where the neonatal outcome was unknown, all remaining 538 women allocated to the treatment group completed their pregnancies and were discharged to home with a live infant.

Table 2

Table 2

Table 3

Table 3

The two groups were similar in duration of pregnancy, either when expressed as the rate of preterm birth (P=.812, OR 1.05, 95% CI 0.7–1.58) or when compared using estimated Kaplan-Meier cumulative probabilities of delivery (Figure 2) (P=.548, hazard ratio 1.02, 95% CI 0.91–1.15) and median gestational age at delivery (Table 2). Factors simultaneously associated with an increased risk of preterm delivery included history of preterm delivery (P=.002, OR 2.71, 95% CI 1.42–5.17), preeclampsia (P<.001, OR 17.56, 95% CI 8.75–35.24), threatened abortion (P=.011, OR 2.83, 95% CI 1.26–6.34), and antepartum hemorrhage (P<.001, OR 3.75, 95% CI 1.91–7.36). Risk of preterm delivery for nulliparous women was similar to that of parous women who had no history of preterm delivery (P=.838, OR 1.05, 95% CI 0.64–1.72).



The type of onset of labor was similar for each group (P=.436). Birth weights were similar in the two groups when expressed either as mean birth weight (P=.117) or expected birth weight for gestational age using charts derived from the local population (P=.103).

There were no differences between the two groups in measures of fetal welfare or health of the newborn (Table 4). These measures included incidence of nonreassuring fetal heart rate traces (P=.264), the need for delivery based on abnormal fetal heart rate patterns (P=.687), the presence of meconium in amniotic fluid (P=.522), cesarean delivery for fetal distress (P=.720), Apgar scores less than 7 at 1 or 5 minutes (P=.403 and P=.988, respectively), the need for resuscitation of the newborn (P=.133), umbilical artery pH (P=.371), Pco2 (P=.867) and base excess (P=.864) values, or the need for admission to the special care nursery (P=.119, OR 1.36, 95% CI 0.92–2.01).

Table 4

Table 4

The mean gestational age at the time of the periodontal screening examination was 18.2 weeks (Table 5). There were no differences between the two groups at recruitment in measures of inflammation (P=.459), plaques (P=.506), bleeding on probing (P=.361), and percentage of tooth sites with probing depth of 4 mm or greater (P=.788).

Table 5

Table 5

Four hundred seventy-six women (88.3%) in the treatment group completed their treatment (Fig. 1). Among the 63 women who did not complete their treatment, 35 did not attend any of their scheduled visits. The success of treatment was measured around 28 weeks of gestation (Table 6). There were significant improvements in all clinical measures of disease afte treatment.

Table 6

Table 6

Back to Top | Article Outline


The purpose of this study was to investigate whether treatment of periodontal disease during midpregnancy prevents complications of pregnancy. Periodontal treatment did not prevent, or cause, preterm birth, fetal growth restriction, or preeclampsia. All other measures of pregnancy outcome were similar in the two groups, with the possible exception of perinatal death. There were four stillbirths and one neonatal death in the control group and no pregnancy losses in the treatment group.

Meta-analysis of the first seven trials of periodontal treatment during pregnancy revealed a possible reduction in preterm birth and incidence of low birth weight.11 These findings from randomized trials added to observations from observational studies4,16 indicating associations between periodontal disease and preterm birth. The results of the present study and those of the next largest trial12 are not supportive of the hypothesis, with both trials providing strong evidence that treatment of periodontal disease is ineffective in preventing early birth. There are many differences, however, between many of the randomized controlled trials that have been reported.11 Only three of the seven trials reported adequate randomization procedures, and only three trials were blinded. Within these various trials was a diversity of patient populations.

The first reported trial involved women of Spanish and local aboriginal descent who were of low socioeconomic status.17 Preterm birth was less frequent in those who had been allocated to receive periodontal therapy (1.1% in the treatment group, 6.4% in the control group, P=.02). The second trial was a pilot study, conducted at the University of Alabama in Birmingham.18 Three hundred sixty-six women were randomly assigned to scaling and root planing, with or without metronidazole, or dental prophylaxis and placebo. Eighty-five percent of women in this trial were African-American. The trial provided some preliminary evidence that periodontal treatment may prevent preterm birth, and that adjunctive treatment with metronidazole is not of benefit and may be harmful. The largest trial reported until now was the OPT Study conducted in the United States and reported in 2006, which observed preterm birth in 12% of women in the treatment group and 12.8% in the control group, a difference that was not statistically significant.12

The finding in the present study of four stillbirths in the control group and none in the treatment group would not in itself be grounds to expect that the treatment was protective for the fetus because the numbers were relatively small, the difference did not achieve statistical significance, and this was not a primary endpoint of the study. There is, however, evidence from other sources suggesting that such a protective effect may be real. First, the finding is consistent with that observed in the next largest randomized controlled trial of periodontal treatment during pregnancy, the OPT Study, reported by Michalowicz et al.12 In that trial, 3 of 407 patients in the treatment group and 10 of 405 patients in the control group had a stillbirth. The authors viewed this finding with particular caution because the numbers were relatively small. If the numbers of stillbirths in the study by Michalowicz et al and the present study are combined by meta-analysis, the reduction in stillbirth after periodontal treatment is statistically significant (P=.02, OR 4.00, 95% CI 1.22–13.10). These two randomized controlled trials have been chosen for this meta-analysis because they are the only ones that share similar study designs.

Second, we have observed previously that women with a history of recent perinatal loss are more likely to have periodontal disease. In a case–control study of 53 women whose pregnancy had resulted in perinatal death compared with 111 matched controls, those women who had experienced a perinatal loss were more likely to have periodontal disease (OR 2.34, 95% CI 1.05–5.47).19

Third, the lethal effects of periodontal pathogens in causing fetal death are well established in animal models, including both hamsters7,8 and sheep.9

Stillbirth, however, was not a primary endpoint of the present study. Despite our previous observations that periodontal disease may increase the risk of fetal death, we were unable to design our study with stillbirth as a primary outcome. To perform such a study would require a sample size that is unachievable within the range of contemporary research funding and opportunity. Hence, the value of combining results from similar studies becomes evident. The OPT Study had design features generally similar to those of the present study,12 suggesting that results from the two trials can be combined with relative confidence. Meta-analysis of the first seven published randomized controlled trials of periodontal treatment during pregnancy, however, did not provide reassurance that stillbirth may be prevented by such treatment.11

In conclusion, the evidence provided by the present study does not support the hypothesis that treatment of periodontal disease in midpregnancy prevents preterm birth, fetal growth restriction, or preeclampsia. A possible beneficial effect in preventing a proportion of stillbirths remains uncertain. Several other randomized controlled trials are currently in progress, and meta-analyses of the results of all studies can be expected to provide conclusive evidence in the future. Studies also need to be performed to investigate any possible benefits from periodontal treatment before conception. In the meantime, the information available to us at this time suggests that periodontal treatment during pregnancy is safe for the woman and her pregnancy, and that any beneficial effects for the child are either nonexistent or likely to be restricted to certain populations or subgroups that have yet to be defined with certainty.

Back to Top | Article Outline


1.Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75–84.
2.Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000;342:1500–7.
3.Goldenberg RL, Culhane JF. Infection as a cause of preterm birth. Clin Perinatol 2003;30:677–700.
4.Xiong X, Buekens P, Fraser WD, Beck J, Offenbacher S. Periodontal disease and adverse pregnancy outcomes: a systematic review. BJOG 2006;113:135–43.
5.Offenbacher S, Katz V, Fertik G, Collins J, Boyd D, Maynor G, et al. Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol 1996;67 suppl:1103–13.
6.Boggess KA, Lieff S, Murtha AP, Moss K, Beck J, Offenbacher S. Maternal periodontal disease is associated with an increased risk for preeclampsia. Obstet Gynecol 2003;101:227–31.
7.Collins JG, Windley HW III, Arnold RR, Offenbacher S. Effects of a Porphyromonas gingivalis infection on inflammatory mediator response and pregnancy outcome in hamsters. Infect Immun 1994;62:4356–61.
8.Collins JG, Smith MA, Arnold RR, Offenbacher S. Effects of Escherichia coli and Porphyromonas gingivalis lipopolysaccharide on pregnancy outcome in the golden hamster. Infect Immun 1994;62:4652–5.
9.Newnham JP, Shub A, Jobe AH, Bird PS, Ikegami M, Nitsos I, et al. The effects of intra-amniotic injection of periodontopathic lipopolysaccharides in sheep. Am J Obstet Gynecol 2005;193:313–21.
10.Offenbacher S, Jared HL, O’Reilly PG, Wells SR, Salvi GE, Lawrence HP, et al. Potential pathogenic mechanisms of periodontitis associated pregnancy complications. Ann Periodontol 1998;3:233–50.
11.Polyzos NP, Polyzos IP, Mauri D, Tzioras S, Tsappi M, Cortinovis I, et al. Effect of periodontal disease treatment during pregnancy on preterm birth incidence: a metaanalysis of randomized trials. Am J Obstet Gynecol 2009;200:225–32.
12.Michalowicz BS, Hodges JS, DiAngelis AJ, Lupo VR, Novak MJ, Ferguson JE, et al; OPT Study. Treatment of periodontal disease and the risk of preterm birth. N Engl J Med 2006;355:1885–94.
13.Cutress TW, Ainamo J, Sardo-Infirri J. The community periodontal index of treatment needs (CPITN) procedure for population groups and individuals. Int Dent J 1987;37:222–33.
14.Gibbs CH, Hirschfeld JW, Lee JG, Low SB, Magnusson I, Thousand RR, et al. Description and clinical evaluation of a new computerized periodontal probe: the Florida probe. J Clin Periodontol 1988;15:137–44.
15.O’Leary TJ, Drake RB, Naylor JE. The plaque control record. J Periodontol 1972;43:38.
16.Vergnes JN, Sixou M. Preterm low birth weight and maternal periodontal status: a meta-analysis. Am J Obstet Gynecol 2007;196:135.e1–7.
17.López NJ, Smith PC, Gutierrez J. Periodontal therapy may reduce the risk of preterm low birth weight in women with periodontal disease: a randomized controlled trial. J Periodontol 2002;73:911–24.
18.Jeffcoat MK, Hauth JC, Geurs NC, Reddy MS, Cliver SP, Hodgkins PM, et al. Periodontal disease and preterm birth: results of a pilot intervention study. J Periodontol 2003;74:1214–8.
19.Shub A, Wong C, Jennings B, Swain JR, Newnham JP. Maternal periodontal disease and perinatal mortality. Aust N Z J Obstet Gynaecol 2009;49:130–6.


© 2009 by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.